All News
🟢 ADMA Biologics is trading 27.48% up in after-hours trading after Q3 revenue beat
ADMA Biologics is trading at $13.36, up 27.48%, in after-hours trading after Q3 revenue beat expectations. - The price followed the November 4, 2026...
Snap Posts Its First-Ever GAAP Profit, So Why Are Investors Heading for the Exit?
Shares slumped nearly 10% after Snap reported a quarter that looked like a breakthrough on paper but left Wall Street cold where it counts most — the top line....
Sezzle Crushes Q3 Estimates and Raises Guidance Again — But Can a Buy-Now-Pay-Later Stock Sustain a 27x Earnings Multiple?
Shares surged as Sezzle delivered a third-quarter earnings beat that blew past already-optimistic forecasts, prompting the buy-now-pay-later lender to raise...
Rapid7 Beats on Earnings and Lifts Its Outlook, but Can a Shrinking Customer Base Sustain the Rally?
Shares of cybersecurity firm Rapid7 surged more than 16% in after-hours trading on November 4 after the company posted third-quarter results that handily...
MKS Inc. beats third quarter estimates with record $1.41B revenue and strong semiconductor growth
MKS Inc. reported record third-quarter 2026 financial results that exceeded the high end of its guidance ranges across all end markets. The performance was...
MercadoLibre's Growth-Over-Profit Gamble: Can $10.75 Billion in Revenue Justify Vanishing Margins?
Shares of MercadoLibre cratered 8.3% to $1,594.83 after the Latin American e-commerce and fintech giant posted Q3 results that once again pitted blockbuster...
Qualcomm Beat Estimates but Lost a Quarter of Its Phone Business — Can Cars and Data Centers Fill the Gap Fast Enough?
Shares of Qualcomm slid 6% to $162.74 after the chipmaker's fiscal fourth-quarter report exposed a widening crack in its foundation: the handset business saw...
Revolution Medicines Obliterates Launch Expectations With $198 Million in Five Weeks — But Can a Still-Unprofitable Biotech Justify a $47 Billion Bet?
Shares of Revolution Medicines surged 10.2% to $220.00 after the company reported that its pancreatic cancer drug generated $197.6 million in net revenue...
Phibro Animal Health first quarter 2027 revenue beats expectations as company maintains annual guidance
Phibro Animal Health reported first quarter 2027 net sales of $386.8 million, surpassing the consensus estimate of $382.4 million, while adjusted diluted EPS...
Magnite Blew Past Every Q3 Target — But Can Streaming Ads Sustain This Breakneck Pace?
Shares surged nearly 10% after the close on November 4 as Magnite delivered a quarter that beat expectations across the board, raising the question of whether...
TaskUs Smashes Q3 Estimates on AI Surge, but Can a Sub-Billion-Dollar Company Keep Winning the AI Outsourcing Race?
Shares of TaskUs jumped 8.2% to $9.34 after the outsourcing specialist delivered a record third quarter that blew past Wall Street's expectations, raising the...
Xperi Inc. beats third quarter 2026 revenue and earnings estimates as advertising revenue surged 280%
Xperi Inc. reported third quarter 2026 revenue of $114.0 million, slightly ahead of the $111.5 million analyst estimate. The company achieved a non-GAAP...
Veracyte Beat Wall Street's Numbers — So Why Did Investors Erase $700 Million in Market Value Overnight?
Shares of Veracyte cratered 17.2% to $43.50 after the cancer diagnostics company reported Q3 results on November 4 that, on paper, looked solid — but came...
MagnaChip's third quarter 2026 results missed estimates as revenue declined 4% year-over-year
MagnaChip reported third quarter 2026 revenue of $44.0 million, hitting the midpoint of internal guidance but falling short of analyst consensus. Performance...
🔴 Zillow Group is trading 17.4% down in after-hours trading on November 4, 2026, after revenue miss
Zillow Group is trading 17.4% lower at $28.00 in after-hours trading following third-quarter results reported after the November 4, 2026, market close, with...
🔴 Veracyte is trading 17.17% down in after-hours trading after narrowing FY2026 revenue outlook
Following the November 4 regular-session close, Veracyte is trading at $43.50, down 17.17%, after management narrowed the upper end of its FY2026 revenue...
🟢 USG.NZ is trading 3.07% up on November 4, 2026, as midterm sweep eased election uncertainty
USG.NZ is trading at NZD 16.80, up 3.07%, in line with stronger U.S. market sentiment after Democrats’ midterm sweep eased election uncertainty. - No clear...
🟢 Taskus is trading 8.2% up in after-hours trading after record Q3 revenue beat estimates
Taskus is trading at $9.34 (+8.23%) in after-hours trading after its November 4, 2026, earnings release reported record Q3 revenue of $314.7 million, beating...
GRAIL's Cancer Test Sells More Units But Less Revenue — Is the Growth Story Breaking Down?
Shares of GRAIL cratered 12.5% to $125.75 after the cancer-detection company's third-quarter revenue landed far below what Wall Street expected, raising hard...
Aris Mining's third quarter 2026 revenue of $295M significantly beat estimates despite higher AISC
Aris Mining reported strong top-line results for the third quarter of 2026, with revenue significantly exceeding analyst expectations due to high realized gold...